Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here’s another from 10k and he does call it a phase 3. Again we know now it’s all HORSESHIT! Still funny looking back at these epic fails though.
In addition, Dr. Günzburg and Dr. Salmons will be intimately involved in the Company’s Phase 2b clinical trial that will be conducted in Australia by one of the foremost CROs in that country, Clinical Network Services (CNS) Pty Ltd (“CNS”). This Phase 2b clinical trial, which can be viewed as “mini” Phase 3 trial, will compare the Company’s treatment “head to head” with the best available therapy which is currently Celgene’s drug Abraxane ® in combination with gemcitabine (this was the first drug approved by the FDA to treat pancreatic cancer; the trade name of gemcitabine is “Gemzar ® ”) to treat advanced, inoperable pancreatic cancer. The participation of Dr. Günzburg and Dr. Salmons is fortunate for the Company because, in addition to being architects of the Cell-in-a-Box ® technology and of Nuvilex’s pancreatic cancer treatment, they: (i) were intimately involved in the original Phase 1/2 clinical trials in advanced, inoperable pancreatic cancer that were carried out several years ago in Europe; and (ii) are exceedingly familiar with CNS and the personnel that will be involved in the Company’s Phase 2b clinical trial.
https://content.edgar-online.com/ExternalLink/EDGAR/0001019687-14-002942.html?hash=0998935038efc99d59ba1bb4d59bb45f3deb01ba14e5c560fbd02170bfe0a004&dest=NUVILEX_10K-EX1004_HTM#NUVILEX_10K-EX1004_HTM
Your right he didn’t say p3 but did say the following. We know now it was all BULLSHIT.
Ken Waggoner
“We are well underway in completing the necessary steps to commence three clinical trials using our Cell-in-a-Box® technology. The first will be a Phase 2b clinical trial of our pancreatic cancer treatment. Our pancreatic cancer treatment will be compared “head-to-head” with the current best available treatment for the disease. This treatment is the combination of gemcitabine with Celgene’s drug Abraxane®. We expect to begin this clinical trial in the third quarter of 2015.
We are also underway in completing preparations for two other clinical trials related to the “quality of life” of patients with advanced pancreatic cancer and other abdominal tumors. These clinical trials deal with treatments for the: (i) intractable and virtually untreatable pain about 20-25% of patients with advanced pancreatic cancer suffer from; and (ii) accumulation of fluid (knows as ascites) in the abdomen that is extremely uncomfortable for patients with pancreatic cancer and other abdominal tumors. Because ascites fluid can contain cancer cells and these cells can seed and form new tumors, oncologists must frequently remove ascites fluid from patients. This is costly and painful. There is no treatment on the market to slow down the accumulation of ascites fluid. We believe our treatment will. We expect to start both clinical trials late in the third quarter of 2015.”
http://pharmacyte.com/qa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction/
Didn’t wags say p3 to start 3 years ago? See how well that worked.
Do people really still believe the con man?
“didn't kw say they should start this month?”
$PMCB a "Zombie Stock"
A classic "zombie stock" is one that usually is operating on next to nothing and that may be dead and not even know it. A "biotech zombie" is a different animal altogether. In this article we'll take you through the gruesome nature of these stocks and how to watch out for these "living dead" investments.
The Creation of a Biotech Stock and a Monster
A biotech company is usually started by a grant from a local government, a foundation, a university, a wealthy backer or by a venture capitalist investment group. The time frame before investors can expect to see returns often runs in the range of five to 12 years and investors almost always buy into these stocks with the understanding that the payoff has to initially come from either a partnership with a major drug company or an already public biotech company. The real payout will come as the company gets closer to developing a treatment for whatever ailment is targeted. The costs are massive to bring actual products to market and very few ever make it there entirely on their own (if it all).
Let's discuss the most common scenario for creating a publicly traded biotech zombie, using the fake company XYZ BIOTECH.
XYZ BIOTECH decides to go public with a robust business plan and some initial strong pre-clinical lab tests. Overall, it's a healthy company with no signs of future monsterism.
SOUND FAMILIAR?? PMCB Hmmm....
Note: The most common areas for biotech research include cancer, diabetes, AIDS, staph, sepsis, Alzheimer's, skin disease, viral influenza, avian flu and sexual dysfunction.
In order to get a strong interest from the start, startup biotech companies tend to attack more common "target" diseases. There is just too much capital required to get a product developed that would treat an ailment that only affects a few hundred - or even a few thousand - people each year. The growing monster must target the greatest number of people possible if it is to survive.
Chasing Its Goals, Dragging Behind
Now that the monster has been created and is heading toward a target group, it must sustain itself. Biotech zombies will never have genuine revenues, but they may show some revenues on the balance sheet because of interest income, grant payments and study partner funding.
Now, let's say that at some point down the road, usually after the zombie company has spent 50% or more of its initial public offering (IPO) cash and/or partner grant cash, XYZ BIOTECH drops the ball and issues a news release stating that its star treatment (its lead candidate) has failed to meet primary endpoints. The zombie's heart is failing.
Failing to meet its goals means that the robust indications and wonder cure are just not what the previous hype indicated. The XYZ zombie will say it is still evaluating data, and that it is evaluating its molecules for other indications; but, for all practical purposes, the hopes of reaching the major target are gone. At this point, the biotech zombie usually loses its big-buck partner and, as a result, all future financial backing. Therefore, it must decide what it will do going forward.
At this point, XYZ will likely scale down operations, reign in spending and usually send some employees and contracts pink slips. For whatever reason, most of the companies that fall into this scenario usually have between $50 to $150 million in net cash after subtracting intangibles from the hard assets, and then after subtracting their various liabilities. But although the zombie has been battered, it's still alive and continues to stumble along after it's goal.
It's like the author had PMCB in mind when writing this, unbelievable!
The FDA Promotes Further Zombie-ism
If XYZ's candidate is granted a Food and Drug Administration (FDA) "orphan drug" designation, which is given if the candidate would have been a treatment for a condition where no treatment currently exists, the increased attention received from the FDA's designation would cause it to become a full zombie even faster. When the FDA gives an orphan drug designation, it generally requires more data and more tests, which is something a partner company or capitalist backer is not looking to support.
Is a zombie a fraud?
Many of these biotech zombies get labeled as hucksters or frauds, but in many cases it is simply a true a failure in a larger scale testing phase that turns them to zombies. Sometimes it boils down to the FDA making a completely unexpected call. Listening to the subsequent conference calls will provide the best signal of this. If a biotech company is not legitimate, it quickly becomes evident because there are too many public opinion posts and too many online message boards where investors can get information. The end result will usually be a long steady decline for the companies that are run by management that doesn't get it.
Chasing Down Biotech Zombie Stocks | Investopedia http://www.investopedia.com/articles/stocks/07/biotech_zombies.asp#ixzz3wY4sexK8
PMCB. FDA WARNS OF Thwarting a Stem Cell Scheme
Three men were arrested in the United States and charged with 15 counts of criminal activity related to manufacturing, selling and using stem cells without FDA sanction or approval.
According to the criminal indictment, one of the accused, a licensed midwife who operated a maternity care clinic in Texas, obtained umbilical cord blood from birth mothers, telling them it was for “research” purposes. Instead, the midwife sold the cord blood to a laboratory in Arizona which, in turn, sent the blood to a paid consultant at a university in South Carolina. The owner of the laboratory in Arizona was convicted in August 2011 of unlawfully introducing stem cells into interstate commerce. She faces up to 3 years in prison and a fine of up to $10,000.
The consultant, an assistant professor, used university facilities to manufacture stem cell products. He then sent the products back to the lab, which sold them to a man representing himself as a physician licensed in the U.S. The man then traveled to Mexico to perform unapproved stem cell procedures on people suffering from cancer, multiple sclerosis and other autoimmune diseases.
The three defendants allegedly received more than $1.5 million from patients seeking treatment for incurable diseases.
“Scammers like these offer false hope to people with incurable diseases in order to line their own pockets with money,” says Special Agent in Charge Patrick J. Holland of FDA’s Office of Criminal Investigations (OCI), Kansas City Field Office. “FDA will continue to aggressively pursue perpetrators who expose the American public to the dangers of unapproved stem cells and ensure that they are punished to the full extent of the law.”
FDA’s OCI worked the case with the Federal Bureau of Investigations and the Internal Revenue Service’s Criminal Investigations Division.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm286155.htm
PMCB next?
Tired of being manipulated and taken advantage of?
Lied to?
Losing your hard earned money to scams portraying to be legit companies such as PMCB?
Report PMCB and or traders trading on insider information to the SEC!
Inside information has been given in a private Facebook pmcb group, that’s no secret to those here.
The U.S Securities Exchange Commission can and will subpoena Facebook for a list of all messages, comments deleted or not. Become a whistle blower and fight against these criminals. Receive cash rewards agains successful prosecution against those committing these crimes. Fight back against these low life’s!
https://denebleo.sec.gov/TCRExternal/disclaimer.xhtml
For once I agree with you!!! Good job and nice factual post!!
Why’s that?
Quote:
“And I believe the facebook guys don't let everyone in.”
What if I bring my pmcb rose colored glasses?
Why would he need to? The lack of studies confirms CIAB is garbage. Only Lohr and Salmons write about. What have they ever accomplished successfully in the bio field? Nada.
From 1999 old isn’t it. Shows how much has changed. Not.
Pmcb horseshit management. Robbing investors blind for 5 years strong.
Are these serious questions? I would have thought majority of those invested in pmcb knew the background of these two numb skulls.
Quote:
Have you put these questions to Professor Gunzberg?
Or Dr. Mathias Lohr?
Those two have been trying to get CIAB to work and get support for 2 decades. No matter how worthless CIAB is they have unconditional love for the pos. They like longs of pmcb haven’t learned to let go of a failure.
See link:
https://www.nature.com/articles/3300671
It (CIAB) was left behind over a decade ago. No wonder a scammer otc attorney picked it up for a measly 2m.
Quote:
“Is cell in a box being left behind?”
Yes it DOESN’T WORK!! Don’t know how much more obvious it can be.
Quote:
“I keep wondering if there’s something about the technology we don’t know.”
Only way this gets to .10 is after the 10:1 reverse split. After that pmcb will tank again because the only thing left the company has to sell is dreams. CIAB is dead which should be obvious if one reads anything besides the long’s on this board.
I call BULLSHIT! Pmcb is a scam and most are now FINALLY seeing this. Boy I sure would have hated myself for buying into pmcb on hype such as below especially in the mid .30’s. Lmao. I guess the old saying rings true. “A _ _ _ _ and their money soon part.”
QUOTE: “Exciting new opportunities and partner for encapsulated stem cell applications - watch this space!”
Pmcb will never get ind, trials and defiantly not a cure. Companies with a 29m marketcap don’t cure cancer lmao. They will though leave ya broke asking how it happened.
Sad yes, trials what trials? It’s also sad some believe pmcb ISN’T a scam and will lose everything.
It’s sad pmcb uses pancreatic cancer as a way to scam.
That’s the problem nobody wants to use it. Failure. Hell one can buy CIAB kits online (up to 5 experiments, each creating ~120 capsules, each containing between 4,000 and 40,000 cells.)
USD $571.00
Again failure.
http://www.sigmaaldrich.com/catalog/product/sigma/cib001?lang=en®ion=US
Why is it a lot of posts warning of pmcb and management are getting repeated now as new found ideas? It’s good my posts are now unseen or I might keep getting plagiarized.
Report Pharmacyte to the U.S Securities Exchange Commission. Inside info and trading is illegal. Become a whistle blower and fight against these criminals. Receive cash rewards agains successful prosecution against those committing these crimes. Fight back against these low life’s!
https://denebleo.sec.gov/TCRExternal/disclaimer.xhtml
I’m sure ya have. Question is how much money could have been saved by not buying this pos throughout the years? I’ve been watching pmcb since .30’s and it’s been down hill ever since. Been brutal for shareholders hasn’t it?
Quote:
“I’ve heard this a million and one times over the years Frost.”
Sec denied Pmcb registration released 11/6/17. SEC is coming LMAO
https://www.sec.gov/Archives/edgar/data/1157075/000000000017039129/filename1.pdf
No just quitting like Td2 and Dr. Von Hoff did. They became aware the SEC is looking into Pharmacyte releasing inside info and those trading on it.
Stock price and volume clearly shows panic sales before this scam is exposed. Mark it.
Buyer Beware!!
Quote:
“Our doctors and staff are NOT panicking”
Ya can’t as I’ve been preaching for years. Pmcb is a scam meant to deplete hopeful investors cash into kw bank account.
Quote:
“How can we trust the company when they mislead us like this?”
Lol the new base support is .031. Tomorrow pmcb will blow past that again.
Quote:
“any one know what the base support is today”
Time ya get a million shares the stock will do a 10:1 reverse split and tank again. Patients, holding penny stocks is not smart.
Apparently not since nobody is interested in doing anything with CIAB with the exception of con men.
Quote:
“Great technology.”
Pmcb has 3 million and that’s from selling shares. They have nothing except worthless shares. CIAB was a failure and pmcb only asset. Game over.
I never had hope in pmcb and never trusted them. I also believe I shared my theories warned of this scam. Had some heeded my warnings money wouldn’t have been lost.
Pmcb is a scam, garbage, a big joke but please keep buying.
Quote:
“I added more as well. This is a gift”
Why buy it when there are no patent protecting CIAB. If it was good as being proclaimed (only) here generic pharma would have already been all of this.
Buyer Beware
What’s “base support” today for pmcb? I wanna see how fast it blows right through it.
Wow....so looks like $.0385 is the base support today and moving DOWN from there!
You will see. Kw will be gone soon leaving investors broke and confused as to what and how it could happen. He will leave with the millions he’s acquired feeding his flock empty promises.
I’m sorry that the human nature of getting rich quick over powers common sense. Pmcb isn’t.
4 1/2 years and pmcb has done NOTHING with CIAB. Did you know (Cell in a Box) formerly know as NovaCaps was about to start p3 when Austrianova had it?? Don’t ya think pmcb should easily have been able to carry on if it had potential? It doesn’t. Austrianova sold it because it was garbage. They extracted nearly $50m usd from investors before giving up. Sound familiar? It should.
As for partners? What partners? There are none.
http://www.businesswire.com/news/home/20070605005587/en/AUSTRIANOVA-Completes-Closing-35-EURO-Series-Financing#.VZrrBFI8LCT
Quote:
“If you are looking for immediate results you may be investing in the wrong place... Way to much has gone into this technology with way too many partners to see this as some type of SCAM”
The low down is this. Pmcb is a share selling scam. I would not repeat NOT invest another 30% into this especially at higher prices. The technology is ancient and has attracted 0 interest in big pharma in the last 20 years. Just a old penny stock attorney seen the potential to make a few million off selling the idea to naive investors hoping to strike gold. It worked. Ceo has made millions and investors handed the $ to him. If the CC was not proof enough I don’t know what else to tell ya. Maybe sorry for you loss??
Quote:
“Someone please give me the low down as to what is really going on with this stock... I am months and months into it and truly would like to see some direction and progress as to where this company is going. I like the technology and believe it is extremely promising... Are they currently playing with this stock price or is the entire company a bust?
Please Pros and Cons...”
Well said! Gotta know when to fold’em. Many legit companies out there, maybe not so many in otc land but none the less. Add the fact were in a bull market losses can be made up. First step is to cut the losers out of ones portfolio. Pmcb would be the first to get the axe.